Filing Flows › Starling Oncology (STLN) › Q2 2026
Starling Oncology (STLN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Starling Oncology (STLN) reported revenue of $161M for the second quarter 2026 (Q2 2026), +35% from a year earlier and +9% from the quarter before. Operating margin was -2.9%, net loss $9.8M (6.1% of revenue).
Starling Oncology, Q2 2026: revenue $161M (+35% year over year), operating margin -2.9%, net loss $9.8M, operating cash flow $11.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $161M | +9% | +35% |
| Operating profit | −$4.6M | — | — |
| Net earnings | −$9.8M | — | — |
| Operating cash flow | $11.9M | — | — |
| Free cash flow | $11.0M | — | — |
What changed
Revenue was $161.3M in Q2 2026, up 35% year over year and up 9% from the previous quarter. Specialty Pharmacy was the largest line at 61% of revenue. Specialty Pharmacy added $36.0M year over year (up 58%), 87% of the total change. FFS revenue declined 17%.
Operating costs exceeded revenue by $4.6M, an operating margin of -2.9%. Total costs grew 27% against revenue growth of 35%. The fastest-growing cost line was Other operating costs (+31%). The quarter ended with a net loss of $9.8M, wider than the previous quarter's $2.5M loss. Net interest and other expense of $5.2M was the main reason.
Operating cash flow was $11.9M. Non-cash charges added back $1.8M of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items added $18.8M. Capital expenditures of $908K left free cash flow of $11.0M.
Questions
What was Starling Oncology's revenue in the second quarter 2026?
Starling Oncology (STLN) reported revenue of $161M for the second quarter 2026 (Q2 2026), +35% from a year earlier and +9% from the quarter before.
Was Starling Oncology profitable in the second quarter 2026?
Operating loss was $4.6M (-2.9% of revenue) and net loss $9.8M.
Source: Starling Oncology 10-Q on SEC EDGAR.